COMPANY

BioMed Valley Discoveries

Keywords: oncology antibody antibody-drug conjugate cancer ADC Solid Tumor Malignancies Gastrointestinal Cancer BRAF Gene Mutation BRAF Gene Alteration MEK Mutation MEK Alteration MAP2K1 Gene Mutation MAP2K1 Gene Alteration MAP2K2 Gene Mutation MAP2K2 Gene Alteration Acute Myelogenous Leukemia Myelodysplastic Syndrome Diabetic Foot Infection Prosthetic Joint Infections Prosthesis Related Infections [124I]FIAU BVD-523 Clostridium novyi-NT spores

Profile checked Oct 10, 2026

10Trials (company is sponsor)

Timeline

May 26, 2022 Trial start Phase 2: Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies source ↗
Jan 7, 2021 Trial start Phase 2: Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations source ↗
2017-01 Trial start Phase 1: Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers source ↗
2014-11 Trial start 1: Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes source ↗
2013-10 Trial start Phase 1: Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies source ↗
2013-04 Trial start Phase 2: [124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection source ↗
2013-03 Trial start I: Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies source ↗
2012-08 Trial start Phase 2: [124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint source ↗
2011-04 Trial start Phase 1: Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies source ↗
2010-12 Trial start Phase 1: Biodistribution and Dosimetry Evaluation of [124I]FIAU source ↗

Clinical trials (lead sponsor) 10

Record	Title	Phase	Status	Start	Primary completion
NCT05221320	Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies	Phase 2	Terminated	May 26, 2022	May 8, 2024 (actual)
NCT04488003	Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations	Phase 2	Terminated	Jan 7, 2021	Feb 15, 2023 (actual)
NCT01781429	Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies	I	Completed	2013-03	2018-02 (actual)
NCT01924689	Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies	Phase 1	Completed	2013-10	Oct 31, 2017 (actual)
NCT02994732	Absorption, Metabolism and Excretion (AME) of Single Dose Radiolabeled BVD-523 in Volunteers	Phase 1	Completed	2017-01	2017-02 (actual)
NCT02296242	Phase 1/2 Study of the ERK1/2 Inhibitor BVD-523 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndromes	1	Completed	2014-11	Jun 15, 2017 (actual)
NCT01764919	[124I]FIAU PET-CT Scanning in Diagnosing Osteomyelitis in Patients With Diabetic Foot Infection	Phase 2	Terminated	2013-04	2013-07 (actual)
NCT01705496	[124I]FIAU PET-CT Scanning in Patients With Pain in a Prosthetic Knee or Hip Joint	Phase 2	Terminated	2012-08	2013-05 (actual)
NCT01118819	Safety Study of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies	Phase 1	Terminated	2011-04	2013-06 (actual)
NCT01337466	Biodistribution and Dosimetry Evaluation of [124I]FIAU	Phase 1	Completed	2010-12	2012-12 (actual)